Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Business board appointment

Ipsen board appoints Mariette Finet

Analysis based on 7 articles · First reported Sep 18, 2026 · Last updated Sep 18, 2026

Sentiment
0
Attention
0
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

This is a routine board-level governance change at a mid-cap pharmaceutical company and is unlikely to move Ipsen's share price or sector sentiment meaningfully. Investors will focus on whether the new director's scientific and investment advisory background influences Ipsen's pipeline strategy in oncology, rare disease and neuroscience.

pharmaceuticals biotechnology

Ipsen, a French biopharmaceutical company listed on Euronext Paris Paris (IPN) and through a US ADR program (IPSEY), announced on 18 September 2026 the co-optation of Mariette Finet as a Director to its Board of Directors, effective immediately. Finet succeeds Michèle Ollier, who resigned from her director position on 1 August 2026. Finet holds a Doctor of Medicine degree from the University of Nancy and brings more than 35 years of experience in healthcare, pharmaceuticals and life sciences, having begun her career at Laboratoires Beaufour and later holding roles at Beaufour-Ipsen Pharma and Ipsen. Since 2007 she has served in scientific and medical advisory roles at Mayroy and Highrock S.a.r.l., and previously sat on the boards of Lightinderm SAS and Altor BioScience. The board also appointed Finet to its Board Portfolio Committee, replacing Ollier. Her appointment is subject to ratification at the next Annual Shareholders' Meeting, and she will serve the remainder of Ollier's term, which expires at the Annual Shareholders' Meeting approving the financial statements for the year ending 31 December 2026. Following the appointment, Ipsen's board comprises 14 directors, seven women and seven men, including four independent directors and two employee representatives. The change is a routine corporate governance matter with no expected material impact on Ipsen's operations or financial outlook.

50 Michèle Ollier resigned Ipsen
40 Ipsen appointed Mariette Finet
stock
Ipsen is the company making the board appointment; the change is a routine governance matter with no expected material effect on its operations or valuation.
Importance 95.0 Sentiment 0.0
per
Finet is the newly co-opted director of Ipsen and member of its Board Portfolio Committee, bringing over 35 years of healthcare and life sciences experience.
Importance 90.0 Sentiment 0.0
per
Ollier resigned as Ipsen director on 1 August 2026 and is succeeded by Finet for the remainder of her term.
Importance 60.0 Sentiment 0.0
cnt
France is Ipsen's home market and the location of the announcement; the event has no broader impact on the country.
Importance 10.0 Sentiment 0.0
exch
Euronext Paris is the exchange where Ipsen shares are listed; it is mentioned only as the listing venue and is unaffected by the appointment.
Importance 10.0 Sentiment 0.0
oth
The University of Nancy, part of the University of Lorraine, is cited as the source of Finet's medical degree; no market impact.
Importance 5.0 Sentiment 0.0
priv
Mayroy is one of the advisory firms where Finet has served since 2007; mentioned only as background on her experience.
Importance 5.0 Sentiment 0.0
priv
Highrock S.a.r.l. is an advisory firm where Finet has served since 2007; mentioned only as background on her experience.
Importance 5.0 Sentiment 0.0
priv
Lightinderm SAS is a former board seat of Finet; mentioned only as background on her experience.
Importance 5.0 Sentiment 0.0
priv
Altor BioScience is a former board seat of Finet; mentioned only as background on her experience.
Importance 5.0 Sentiment 0.0
France related ↔ Euronext Paris
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.